PMID 19723647

出典: meddic

ニロチニブ
Clin Cancer Res. 2009 Sep 15;15(18):5910-6. Epub 2009 Sep 1.
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P.


文献

  • pubmed
[display]http://www.ncbi.nlm.nih.gov/pubmed/19723647

英文文献

  • Corrigendum: Determinants of Conductive Hearing Loss in Tympanic Membrane Perforation: Correction of the Sixth Author Name.
  • Park H1, Hong SN1, Kim HS1, Han JJ1, Chung J1, Suh MW1, Oh SH1, Chang SO1, Lee JH1.
  • Clinical and experimental otorhinolaryngology.Clin Exp Otorhinolaryngol.2015 Dec;8(4):430. Epub 2015 Nov 10.
  • [This corrects the article on p. 92 in vol. 8, PMID: 26045905.].
  • PMID 26617975
  • Erratum to the presentation of lymph nodes in Hashimoto's thyroiditis on ultrasound.
  • [No authors listed]
  • Gland surgery.Gland Surg.2015 Dec;4(6):E2.
  • [This corrects the article on p. 301 in vol. 4, PMID: 26311120.].
  • PMID 26645015
  • Erratum to abnormality of p16/p38MAPK/p53/Wipl pathway in papillary thyroid cancer.
  • [No authors listed]
  • Gland surgery.Gland Surg.2015 Dec;4(6):E1.
  • [This corrects the article on p. 33 in vol. 1, PMID: 25083425.].
  • PMID 26645014
  • What is the right temperature to cool post-cardiac arrest patients?
  • Chandrasekaran PN1, Dezfulian C1, Polderman KH2.
  • Critical care (London, England).Crit Care.2015 Nov 18;19:406. doi: 10.1186/s13054-015-1134-z.
  • CITATION: Niklas Nielsen, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, Pellis T, Stammet P, Wanscher M, Wise MP, Åneman A, Al-Subaie N, Boesgaard S, Bro-Jeppesen J, Brunetti I, Bugge JF, Hingston CD, Juffermans NP, Koopmans M, Køber L, Lang
  • PMID 26577919

関連リンク

1. Clin Cancer Res. 2009 Sep 15;15(18):5910-6. doi: 10.1158/1078-0432.CCR-09-0542. Epub 2009 Sep 1. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal ...
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract (1). The majority of GISTs (90%) harbor activating mutations in the KIT or platelet-derived growth factor receptor α (PDGFRA ...
Gmail - What's new for 'Cancer Pain' in PubMed Kjaersgaard M, Edslev PW, Hasle H. Pediatr Blood Cancer. 2009 Aug 31. [Epub ahead of print] PMID: 19722275 [PubMed - as supplied by publisher] Related Articles 4: Peritoneal ...


★リンクテーブル★
先読みニロチニブ
関連記事PMI」「PM

ニロチニブ」

  [★]

nilotinib
タシグナ
開発名
AMN107
マブダチ
  • チロシンキナーゼ阻害薬

効能又は効果

  • イマチニブ抵抗性の慢性期又は移行期の慢性骨髄性白血病(タシグナカプセル200mg)

添付文書

  • タシグナカプセル200mg
[display]http://www.info.pmda.go.jp/go/pack/4291021M1020_1_04/4291021M1020_1_04?view=body

文献

  • E. Weisberg, P.W. Manley and W. Breitenstein et al., Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl, Cancer Cell 7 (2005), pp. 129-141, PMID 19467857
nilotinib (formerly AMN107), a second-generation oral TKI, engineered to specifically inhibit KIT, PDGFRa and BCR-ABL.
Smaller phase I/II trials or retrospective series have suggested efficacy of nilotinib(22),

sorafenib(33,34) and IPI-504(35) after imatinib and/or sunitinib failure.

nilotinib 22,
22. Blay JY, Casali PG, Reichardt P, et al. A phase I study of

nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update. J Clin Oncol 2008:26. Abstract 10553.

sorafenib 33,34
33. Gelderblom H, Montemurro M, Schu¨ tte J, et al. Sorafenib

fourth-line treatment in imatinib, sunitinib, and nilotinib resistant metastatic GIST: a retrospective analysis. ASCO Gastrointestinal Cancers Symposium 2009; [Abstract 51].

抄録が存在しない
34. Wiebe L, Kasza KE, Maki RG, et al. Activity of sorafenib (SOR)

in patients (pts) with imatinib (IM) and sunitinib (SU)- resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 2008:26. Abstract 10502.

抄録が存在しない
IPI-504 35
35. Wagner AJ, Morgan JA, Chugh R, et al. Inhibition of heat shock

protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from phase I trial. ASCO Meeting Abstracts 2008;26 [Abstract 10503].

  • Schlemmer M, Schinwald N, Bruns C, Berger F, Reichardt P., Response to Nilotinib as a First-Line Treatment for Metastatic Gastrointestinal Stromal Tumors., J Gastrointest Cancer. 2010 Oct 5. [Epub ahead of print]; PMID 20922581
ONCLUSION: This is the first report demonstrating the feasibility of nilotinib (400 mg bid) for the first-line treatment of metastatic GIST. Furthermore, these results underscore that responses to TKIs may be underestimated by Response Evaluation Criteria in Solid Tumors.


PMI」

  [★]


PM」

  [★]




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡